Skip to main content

News & Events

News & Announcements

UMB & SNBL CPC Announce the Expansion of their Collaboration to Include Patient Identification/Recruitment for Enrollment into Early Phase

The complexity of clinical protocols in the early-phase clinical trial industry is continuing to increase at a rapid pace, including the need for enrollment of patients with acute and chronic diseases into Phase I and Phase II trials. In order to remain at the forefront of these trends, SNBL CPC is very pleased to expand its collaborative relationship, with University of Maryland, Baltimore (UMB), by working directly with the University of Maryland School of Medicine faculty physicians. This relationship will make patient recruitment services accessible to the biopharmaceutical industry within an even broader range of diseases.

The carefully developed plan for collaboration will allow for patient referrals across all disease states/departments, utilization of specialty equipment/testing at the University, and physician participation as a Primary Investigator or Sub Investigator, in their area of expertise. Patients enrolled will have access to all specialty and subspecialty services available at the University of Maryland Medical Center. Additionally, the University of Maryland School of Medicine faculty physicians will be integrally involved in the care that patients receive. The collaboration is a long standing effort between the President of the University Dr. Jay A. Perman, Dr. E. Albert Reece, the Dean of the School of Medicine, and Dr. Ryoichi Nagata, Chairman and CEO of SNBL Group, and Takeshi Yamakawa, CEO and President of SNBL CPC.

Click here to read the entire PR Web story